{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:28:25Z","timestamp":1787668105441,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have become one of the core drugs for the comprehensive treatment of advanced gastric cancer. As a representative domestic PD-1 inhibitor, sintilimab has shown significant efficacy in clinical application, but the management of immune-related adverse events (irAEs) remains a clinical challenge. Among them, the incidence of immune-related acute kidney injury (ir-AKI) is only 16.5%\u221217%, but it is mainly manifested as acute interstitial nephritis (AIN), which can progress to irreversible renal failure in severe cases. In particular, when ICIs are combined with potentially nephrotoxic chemotherapeutic drugs (e.g., oxaliplatin), the difficulty of etiological identification increases. Renal biopsy, the gold standard for diagnosis, cannot be performed in the presence of contraindications such as severe thrombocytopenia, further exacerbating the dilemma of diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary<\/jats:title>\n                    <jats:p>\n                      This paper reports a 68-year-old male patient with gastric antrum adenocarcinoma (cT4aN2M0, stage III) who developed progressive elevation of serum creatinine (from a baseline of 89 \u03bcmol\/L to 663 \u03bcmol\/L) accompanied by scattered erythematous papules all over the body, severe thrombocytopenia (minimum 24 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L), renal anemia and other multisystem irAEs after 3 cycles of neoadjuvant therapy with sintilimab combined with oxaliplatin-based regimen. Due to the absolute contraindication of renal biopsy caused by severe thrombocytopenia, clinically presumed sintilimab-associated AIN was diagnosed by comprehensively analyzing the medication timeline, clinical phenotype, laboratory examinations and imaging results, and excluding other causes of renal injury. An individualized glucocorticoid therapy (methylprednisolone 80 mg bid intravenous infusion for 3 days \u2192 80 mg qd \u2192 50 mg qd gradual tapering) was adopted, combined with symptomatic supportive treatment. The patient's renal function recovered significantly (serum creatinine decreased to 182 \u03bcmol\/L), platelet count returned to the normal range (184 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L), skin rash resolved completely, and the patient was discharged in a stable condition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sintilimab-associated AIN can present with the coexistence of multisystem irAEs. In the presence of contraindications to renal biopsy, comprehensive assessment based on medication timeline, clinical phenotype, laboratory indicators and treatment response is the core of diagnosis. Early initiation of individualized glucocorticoid therapy can effectively reverse renal function injury, and multidisciplinary team (MDT) collaboration is the key to optimizing the management of complex irAEs. This case provides a feasible diagnosis and treatment pathway for similar clinical dilemmas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1825181","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:48:01Z","timestamp":1779770881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Sintilimab-associated acute interstitial nephritis in a patient with severe thrombocytopenia: clinical diagnosis and treatment strategy when renal biopsy is contraindicated"],"prefix":"10.3389","volume":"13","author":[{"given":"Zikai","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hui'an County Hospital","place":["Quanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the First Affiliated Hospital of Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","article-title":"Current status of immune checkpoint inhibitors for gastric cancer","volume":"23","author":"Kono","year":"2020","journal-title":"Gastric Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00134-025-08155-x","article-title":"Life-threatening immune-related adverse events in the intensive care unit: a narrative review","volume":"51","author":"Pichon","year":"2025","journal-title":"Intensive Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e006222","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"B9","unstructured":"Innovent\n              Biologics Inc\n            \n          \n          Package Insert of Sintilimab Injection (Daboshu\n          \n          2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/ckj\/sfac109","article-title":"Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study","volume":"15","author":"G\u00e9rard","year":"2022","journal-title":"Clin Kidney J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1182\/blood.2019003810","article-title":"How I treat microangiopathic hemolytic anemia in patients with cancer","volume":"137","author":"Thomas","year":"2021","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/1060028014526160","article-title":"Oxaliplatin-induced renal tubular vacuolization","volume":"48","author":"Joybari","year":"2014","journal-title":"Ann Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ckj\/sft148","article-title":"Severe acute tubular necrosis observed subsequent to oxaliplatin administration","volume":"7","author":"Filewod","year":"2014","journal-title":"Clin Kidney J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jpainsymman.2017.07.033","article-title":"Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer","volume":"54","author":"Griffith","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3760\/cma.j.cn441217-20240618-00627","article-title":"Chinese expert consensus on the management of renal immune-related adverse events caused by immune checkpoint inhibitors (2025 edition)","volume":"41","year":"2025","journal-title":"Chin J Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3779\/j.issn.1009-3419.2019.10.06","article-title":"Recommendations for the diagnosis and treatment of immune checkpoint inhibitor-associated cutaneous adverse reactions","volume":"22","author":"Si","year":"2019","journal-title":"Chin J Lung Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onconephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal complications of immune checkpoint blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e002886","DOI":"10.1136\/jitc-2021-002886","article-title":"Effect of a multidisciplinary severe immunotherapy complications service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer","volume":"9","author":"Zubiri","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.7326\/0003-4819-119-12-199312150-00007","article-title":"Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1825181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:48:26Z","timestamp":1779770906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1825181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":25,"alternative-id":["10.3389\/fmed.2026.1825181"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1825181","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"1825181"}}